Early Pain Reduction Can Predict Treatment Response: Results of Integrated Efficacy Analyses of a Once-Daily Gastroretentive Formulation of Gabapentin in Patients with Postherpetic Neuralgia

Pain Medicine (United States)

Volumn 13, Issue 8, 2012, Pages 1059-1066

  Jensen, Mark P ^a   Hsu, Ping H ^b   Vanhove, Geertrui F ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Depomed   (United States)

Author keywords

Early treatment response; Gastroretentive gabapentin; PHN; Postherpetic neuralgia; Response predictor; Sensitivity; Specificity

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUMERICAL PAIN RATING SCALE; POSTHERPETIC NEURALGIA; RATING SCALE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 84865284813     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01427.x     Document Type: Article

References (26)

1. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med 2009;122(10 suppl):S22-32.
2. Dworkin RH, O'Connor AB, Audette J, etal. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85(3 suppl):S3-14. Epub 2010/03/17.
3. Attal N, Cruccu G, Baron R, etal. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88. Epub 2010/04/21.
4. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: A practical guide for the clinician. CMAJ 2006;175(3):265-75. Epub 2006/08/02.
5. Woolf CJ, Bennett GJ, Doherty M, etal. Towards a mechanism-based classification of pain? Pain 1998;77(3):227-9.
6. Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological medhanisms, and treatment. Lancet Neurol 2010;9(8):807-19.
7. Nierenberg AA, Mclean NE, Alpert JE, etal. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152:1500-3.
8. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: Cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999;32(2):56-60.
9. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systemic review and meta-analysis. Arch Gen Psychiatry 2006;63(11):1217-23.
10. Pollack MH, Rapaport MH, Fayyad R, etal. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res 2002;36(4):229-36. Epub 2002/08/23.
11. Downing RW, Rickels K. Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 1985;72(6):522-8.
12. Rynn M, Khalid-Khan S, Garcia-Espana JF, Etemad B, Rickels K. Early response and 8-week treatment outcome in GAD. Depress Anxiety 2006;23(8):461-5.
13. Pollack MH, Kornstein SG, Spann ME, etal. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 2008;42(14):1176-84.
14. Baldwin DS, Tiwari N. The pharmacologic treatment of patients with generalized anxiety disorder: Where are we now and where are we going? CNS Spectr 2009;14(suppl 3):5-12.
15. Baldwin DS, Schweizer E, Xu Y, Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? Eur Neuropsychopharmacol 2012;22(2):137-42.
16. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63(6):959-65.
17. Neurontin® (gabapentin) Capules, Neurontin® (gabapentin) tablets, Neurontin® (gabapentin) oral solution. US prescribing information. April 2009. Available at: http://www.pfizer.com/files/products/uspi_neurontin.pdf (accessed January 29, 2011).
18. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10(2):276-81.
19. Schwartz S, Fonseca V, Berner B, etal. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29:759-64.
20. Fourcroy JL, Berner B, Chiang YK, etal. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005;49(10):4137-43.
21. GRALISE (gabapentin) tablets. US prescribing information. January 2011. Available at: http://www.gralise.com/lib/PDFS/GRALISE_PI.pdf (accessed Feburary 3, 2011).
22. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: A randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2010;30(11):765-76.
23. Sang C, Sathyanarayana R, Sweeney M. Once-daily gabapentin for the treatment of postherpetic neuralgia. Clin J Pain 2012 (in press).
24. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58. Epub 2001/11/03.
25. Irving G, Jensen M, Cramer M, etal. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: Results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25(3):185-92.
26. Johnson PBL, Halpern R, Sathyanarayana R, Sweeney M. Titration with gabapentin and pregabalin in patients with postherpetic neuralgia (PHN). Clin Drug Invest 2012 (submitted for publication).